Recurrent Glioblastoma Planned for Reoperation Clinical Trial
Official title:
Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma Multiforme Prior to and After Secondary Resection: an Open-label Phase I/II Trial.
Patupilone trial for patients with recurrent glioblastoma, which are planned for
re-operation. Objectives: prolongation of PFS compared to patients with re-operation only,
Patupilone tumor concentrations, pharmacokinetic, Perfusion in MRI pre - and post Patupilone.
Translational research of tumor tissue exposed to patupilone.
- Trial with medicinal product
Prior to and after re-operation patients with recurrent glioblastoma receive the
investigational drug Patupilone, a tubulin-inhibitor.
The purpose of the trial is to prolong PFS in this patient population. Patupilone is already
used in clinical trials of other tumor entities such as ovarian cancer, breast and lung
cancer. Side effects are expected to be manageable.
;